USD
+$0.00
(+0.00%
)At Close (As of Oct 13, 2025)
$44.55M
Market Cap
-
P/E Ratio
-0.91
EPS
$3.48
52 Week High
$0.85
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | -$60K |
Total Revenue | $0 |
Cost Of Revenue | $60K |
Costof Goods And Services Sold | $60K |
Operating Income | -$36M |
Selling General And Administrative | $13M |
Research And Development | $23M |
Operating Expenses | $36M |
Investment Income Net | - |
Net Interest Income | -$2.2M |
Interest Income | $2.5M |
Interest Expense | $4.7M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $60K |
Income Before Tax | -$38M |
Income Tax Expense | -$869K |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$38M |
Comprehensive Income Net Of Tax | - |
Ebit | -$34M |
Ebitda | -$34M |
Net Income | -$38M |
Field | Value (USD) |
---|---|
Total Assets | $45M |
Total Current Assets | $45M |
Cash And Cash Equivalents At Carrying Value | $42M |
Cash And Short Term Investments | $42M |
Inventory | - |
Current Net Receivables | - |
Total Non Current Assets | $304K |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | - |
Intangible Assets Excluding Goodwill | - |
Goodwill | - |
Investments | - |
Long Term Investments | - |
Short Term Investments | - |
Other Current Assets | $3.4M |
Other Non Current Assets | - |
Total Liabilities | $26M |
Total Current Liabilities | $17M |
Current Accounts Payable | $1.7M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $13M |
Total Non Current Liabilities | $9.3M |
Capital Lease Obligations | $123K |
Long Term Debt | $9.2M |
Current Long Term Debt | $13M |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $22M |
Other Current Liabilities | $2.8M |
Other Non Current Liabilities | - |
Total Shareholder Equity | $19M |
Treasury Stock | - |
Retained Earnings | -$182M |
Common Stock | $13K |
Common Stock Shares Outstanding | $36M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$35M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $21K |
Capital Expenditures | $29K |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | -$29K |
Cashflow From Financing | $20M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$38M |
Field | Value (USD) |
---|---|
Gross Profit | -$60K |
Total Revenue | $0 |
Cost Of Revenue | $60K |
Costof Goods And Services Sold | $60K |
Operating Income | -$36M |
Selling General And Administrative | $13M |
Research And Development | $23M |
Operating Expenses | $36M |
Investment Income Net | - |
Net Interest Income | -$2.2M |
Interest Income | $2.5M |
Interest Expense | $4.7M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $60K |
Income Before Tax | -$38M |
Income Tax Expense | -$869K |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$38M |
Comprehensive Income Net Of Tax | - |
Ebit | -$34M |
Ebitda | -$34M |
Net Income | -$38M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
PDS Biotechnology Corporation (PDSB), based in Florham Park, New Jersey, is a clinical-phase biopharmaceutical company dedicated to advancing innovative cancer immunotherapies. The company leverages its proprietary Versamune® platform to create multifunctional therapies designed to enhance the immune response against cancer. PDSB's lead candidate, PDS0101, is currently in clinical trials for the treatment of HPV-related cancers, demonstrating promising potential to transform cancer treatment paradigms. With a strong focus on efficacy and safety, PDSB aims to address significant unmet needs in oncology, positioning itself as a key player in the biopharmaceutical landscape.